Hemab Therapeutics, a clinical-stage biotech company focused on blood coagulation therapies, completed its upsized initial public offering (IPO) by selling 19,262,500 shares at $18 each, including full exercise of underwriters' options. The IPO raised approximately $346.7 million in gross proceeds. Hemab's shares began trading on the Nasdaq Global Select Market on May 1, 2026, under the ticker symbol COAG. The funds will support Hemab's development of innovative treatments for bleeding and thrombotic disorders, including therapies for Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease.
The Dolphin Company's current management proposed selling its main assets in Mexico to Delphinus Blue Planet, a Grupo Xcaret subsidiary, for $20 million. This deal would give Delphinus control over more than 90% of dolphin habitats in Mexico, creatin...
Johnson & Johnson has reached a historic $5.5 billion settlement to resolve claims from about 70,000 women and families alleging its talc products, including Johnson's Baby Powder, contained asbestos and caused cancers such as ovarian cancer and meso...
Catalyst Acquisition Corp. announced the pricing of its initial public offering (IPO) at $10 per unit, raising $200 million by offering 20 million units. The units, each including one Class A ordinary share and a partial share right, will begin tradi...
The US dollar index surged to a 13-month high driven by growing speculation of a Federal Reserve rate hike amid persistent inflation and high energy prices. This strengthened dollar has pressured Bitcoin and Ethereum, which typically move inversely t...
Highlander Silver has transformed into a debt-free precious metals company with diversified assets including Mercedes, Corani, and San Luis. The acquisition of Bear Creek reset its capital structure, eliminating debt and burdensome streams, positioni...
